Naobios

Naobios and Tokyo Metropolitan Institute of Medical Science partner to develop new live-attenuated vaccine against mpox

 Partnership aims to commercialize new mpox vaccine – with higher level of safety – by 2027 23 October 2025 — Nantes, France, and Tokyo, Japan — Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of virus-based products, and the Tokyo Metropolitan Institute of Medical Science (TMIMS), today…
Operating office 6 rue Alain Bombard 44800 Saint-Herblain

33249620510